, Tracking Stock Market Picks
Enter Symbol:
Intermune, Inc. (ITMN) [hlAlert]

up 96.49 %

Intermune, Inc. (ITMN) rated Outperform with price target $24 by Robert W. Baird

Posted on: Friday,  Jan 4, 2013  8:25 AM ET by Robert W. Baird

Robert W. Baird rated Outperform Intermune, Inc. (NASDAQ: ITMN) on 01/04/2013. Previously Robert W. Baird rated Outperform Intermune, Inc. (NASDAQ: ITMN) on
12/20/2010., when the stock price was $37.61. Since then, Intermune, Inc. has gained 96.49% as of 09/26/2014's recent price of $73.90.
If you would have followed the previous Robert W. Baird's recommendation on ITMN, you would have gained 96.49% of your investment in 1376 days.

InterMune Pharmaceuticals Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other disease areas, several of which are in mid-or advanced-stage human testing, known as clinical trials.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/4/2013 8:25 AM Buy
10.43 24.00
as of 12/13/2013
1 Week up  1.45 %
1 Month up  7.90 %
3 Months down  -8.65 %
1 YTD up  43.75 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/20/2010 8:25 AM Buy
37.61 47.00
8/13/2008 8:25 AM Hold
17.70 21.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy